An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis
Latest Information Update: 08 Dec 2024
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms STELARA
- Sponsors Janssen-Cilag
- 13 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2024 Planned number of patients changed from 75 to 133.
- 07 Jun 2021 Planned End Date changed from 15 Sep 2026 to 31 Aug 2032.